Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zolbetuximab by Astellas Pharma for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Zolbetuximab is under clinical development by Astellas Pharma and currently in Pre-Registration for Adenocarcinoma Of The Gastroesophageal Junction. According to...
Zolbetuximab by Astellas Pharma for Gastric Cancer: Likelihood of Approval
Zolbetuximab is under clinical development by Astellas Pharma and currently in Pre-Registration for Gastric Cancer. According to GlobalData, Pre-Registration drugs...
ASP-4396 by Astellas Pharma for Solid Tumor: Likelihood of Approval
ASP-4396 is under clinical development by Astellas Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
ASP-3082 by Astellas Pharma for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
ASP-3082 is under clinical development by Astellas Pharma and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Enfortumab vedotin by Astellas Pharma for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....
Enfortumab vedotin by Astellas Pharma for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase III for Transitional Cell Carcinoma (Urothelial Cell...
Enfortumab vedotin by Astellas Pharma for Epithelial Ovarian Cancer: Likelihood of Approval
Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase I for Epithelial Ovarian Cancer. According to...
Enfortumab vedotin by Astellas Pharma for Fallopian Tube Cancer: Likelihood of Approval
Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase I for Fallopian Tube Cancer. According to...
Enfortumab vedotin by Astellas Pharma for Peritoneal Cancer: Likelihood of Approval
Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase I for Peritoneal Cancer. According to GlobalData,...
ASP-3082 by Astellas Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval
ASP-3082 is under clinical development by Astellas Pharma and currently in Phase I for Non-Small Cell Lung Cancer. According to...
ASP-3082 by Astellas Pharma for Colorectal Cancer: Likelihood of Approval
ASP-3082 is under clinical development by Astellas Pharma and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
ASP-7317 by Astellas Pharma for Dry (Atrophic) Macular Degeneration: Likelihood of Approval
ASP-7317 is under clinical development by Astellas Pharma and currently in Phase II for Dry (Atrophic) Macular Degeneration. According to...
ASP-7317 by Astellas Pharma for Juvenile Macular Degeneration (Stargardt Disease): Likelihood of Approval
ASP-7317 is under clinical development by Astellas Pharma and currently in Phase II for Juvenile Macular Degeneration (Stargardt Disease). According...
ASP-2802 by Astellas Pharma for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to...
ASP-2802 by Astellas Pharma for Follicular Lymphoma: Likelihood of Approval
ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...
ASP-2802 by Astellas Pharma for T-Cell Lymphomas: Likelihood of Approval
ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for T-Cell Lymphomas. According to GlobalData, Phase...
ASP-2802 by Astellas Pharma for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
Ramosetron by Astellas Pharma for Fecal Incontinence: Likelihood of Approval
Ramosetron is under clinical development by Astellas Pharma and currently in Phase III for Fecal Incontinence. According to GlobalData, Phase...
Mirabegron ER by Astellas Pharma for Esophageal Achalasia: Likelihood of Approval
Mirabegron ER is under clinical development by Astellas Pharma and currently in Phase I for Esophageal Achalasia. According to GlobalData,...
ASP-2802 by Astellas Pharma for Marginal Zone B-cell Lymphoma: Likelihood of Approval
ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for Marginal Zone B-cell Lymphoma. According to...